Menu
© 2019 All rights reserved.
TMC Life Sciences Berhad Co. No.: 200301021989 (624409-A)
Aged 49, Malaysian
Dato’ Dr. Adzuan Abdul Rahman joined TMC Life Sciences Berhad as Group Chief Executive Officer on 10 February 2025. He is also currently the Regional Senior Director of Thomson Medical Group.
Dato’ Dr. Adzuan is a seasoned healthcare leader and entrepreneur with over 20 years of experience in clinical practice, hospital management, and corporate strategy. His career spans leadership roles across Malaysia, Singapore, Hong Kong, and the broader Southeast Asia region, driving innovation, operational excellence, and business growth in the healthcare sector.
Trained as a doctor in the United Kingdom, Dato’ Dr. Adzuan began his career in medical practice before expanding into corporate healthcare after earning an MBA from IMD Business School, Switzerland. He has since held key executive roles at Parkway Laboratories, Gleneagles Hospital Kuala Lumpur, and Parkway East Hospital, where he spearheaded operational improvements, patient care enhancements, and strong financial performance.
At idsMED Group, he served as Regional Managing Director and Executive Vice President, leading the company’s strategic expansion and business optimisation. Most recently, he co-founded Novotec Pte Ltd, integrating Generative AI and innovative technologies into healthcare.
He holds a Bachelor of Medicine, Surgery, and Obstetrics from Queen’s University Belfast and has completed executive education in Mergers & Acquisitions at Imperial College Business School, UK.
Dato’ Dr. Adzuan does not hold any directorship in other public companies and listed issuers in Malaysia. He has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, he has no conflict of interest with the Company.
Aged 53, Malaysian
Mr. Wong Yu Chee brings over 28 years of extensive experience in finance, audit, accounting, and tax compliance services in Malaysia and Shanghai.
Mr. Wong began his career in 1996 as an auditor at a local audit firm. In 1997, he joined Coopers & Lybrand, now known as PricewaterhouseCoopers PLT. (“Pwc”), where he spent eight years specialising in assurance assignments for large
multinational companies, public listed companies across various industries, Initial Public Offerings (“IPO”), and corporate exercises.
Following his tenure at PwC, Mr. Wong served as a Finance Manager at GlaxoSmithKline before relocating to Shanghai in late 2005 to join Ernst & Young. During his three-year tenure at Ernst & Young Shanghai, he focused on statutory audit assignments, IPO assurance assignments, corporate exercises, and United States audit assignments. Subsequently, Mr. Wong joined TMF Shanghai, where he led accounting and tax compliance services for two years.
In 2010, Mr. Wong returned to Malaysia as the Director of Accounting & Tax Compliance Services at TMF Malaysia, providing assistance to businesses in accounting and tax compliance, including Goods and Services Tax advisory services. In 2015, he joined PCA Corporate Services Sdn. Bhd. as the Group Chief Operating Officer before joining the Company as Group Chief Financial Officer on 3 August 2015.
Mr. Wong holds the designation of Fellow Member of the Association of Chartered Certified Accountants (FCCA), member of the Malaysian Institute of Accountants (MIA) – Chartered Accountant (M), and Associate Member of the Chartered Tax Institute of Malaysia (ACTIM).
Mr. Wong does not hold any directorship in other public companies and listed issuers in Malaysia. He has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, he has no conflict of interest with the Company.
Aged 44, Malaysian
Dr Savitha Dharan was appointed Chief Executive Officer of Thomson Hospitals Sdn. Bhd. on 1 July 2026.
Dr Savitha is an accomplished healthcare leader with over 20 years of experience spanning clinical practice, hospital operations, strategic partnerships, business development, and executive leadership. She has built a distinguished career driving organisational transformation, operational excellence, and sustainable growth across leading private healthcare institutions in Malaysia.
Following a decade in clinical practice across both the public and private healthcare sectors, Dr Savitha transitioned into healthcare management. She held a series of progressive leadership positions within Ramsay Sime Darby Health Care, including Head of Department and Medical Officer of the Health Screening Centre, Senior Manager of Patient Administration, Head of Strategic Partnerships, and Group Head of Business Development. She subsequently served as Chief Executive Officer of TAGS Chiropractic & Rehabilitation, ALTY Orthopaedic Hospital, and most recently, ParkCity Medical Centre, where she led strategic transformation, service innovation, and operational performance.
Dr Savitha holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor in the Art of Obstetrics (MB BCh BAO) from the Royal College of Surgeons in Ireland (RCSI) and has completed executive education in Managing Health Care Delivery at Harvard Business School.
Dr Savitha does not hold any directorship in other public companies and listed issuers in Malaysia. She has no family relationship with any Director and/or major shareholder of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. She also has no conflict of interest with the Company.
Aged 47, Malaysian
Ms Ng Yee Voon is the Senior General Manager of TMC Fertility Holdings Sdn. Bhd. She brings with her over 20 years of experience in the Malaysian healthcare sector, including in starting and developing home healthcare and oncology services for hospitals and managing the multidisciplinary allied health division. She was appointed to her current role in May 2026, where she leads the organisation with a clear focus on strategic growth, clinical quality, and patient-centric care.
Known for her ability to lead multidisciplinary teams and deliver sustainable organisational transformation, Ms. Ng has successfully launched new healthcare service lines, established strategic referral networks, led accreditation initiatives, and driven business expansion across multiple healthcare settings. Her leadership approach combines strategic thinking, commercial acumen, and a commitment to clinical quality, enabling her to navigate complex healthcare environments and achieve meaningful outcomes.
Ms. Ng holds a Master of Business Administration from Lancaster University and Sunway University, and a Master of Science in Nutrition from Texas A&M University, USA. Her combination of healthcare expertise and business leadership experience has enabled her to successfully lead complex healthcare operations, develop new service lines, and drive sustainable organisational growth across the healthcare continuum.
Ms. Ng Yee Voon does not hold any directorship in other public companies and listed issuer in Malaysia. She has no family relationships with any Director and/or major shareholders of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, she has no conflicts of interest with the Company.
Aged 49, Malaysian
Dr. Siva Kumaran Jayaraman joined Thomson Hospitals Sdn. Bhd. as Chief Operating Officer (Clinical) in December 2022. He is currently the Chief Operating Officer (COO) of Thomson Hospitals Sdn. Bhd.
He possessed over a decade of clinical experience in the government sector. Prior to joining Thomson Hospitals Sdn. Bhd., Dr. Siva Kumaran has held senior management positions at two large public hospitals. During his tenure at Hospital Selayang, he established a new medico-legal unit and in his capacity as Deputy Director (Surgical Services) at Hospital Selayang, he oversaw the enhancement of surgical disciplines and patient care.
In February 2022, Dr. Siva Kumaran became Deputy Director 1 at Hospital Serdang, managing a 1,000-bed hospital with 34 specialties. His role encompassed managing clinical services, new projects, regulatory compliance, and ensuring high standards of patient care. His leadership, critical thinking, and problem-solving skills were crucial in maintaining smooth hospital operations in high-pressure environments.
Since joining Thomson Hospitals Sdn. Bhd., Dr. Siva Kumaran has pursued strategic and efficient improvement of the hospital’s operation and clinical services. His experience in managing large tertiary hospitals has been key to driving Thomson Hospitals Sdn. Bhd.’s strategic objectives and enhancing patient care quality.
As COO, Dr. Siva Kumaran is committed to Thomson Hospitals Sdn. Bhd.’s mission of helping people live healthier lives by providing accessible, accountable, and sustainable healthcare. He aims to foster continuous improvement and innovation, expand services, integrate advanced medical technologies, and ensure Thomson Hospitals Sdn. Bhd., remains a leader in healthcare delivery in Malaysia.
He holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Manipal Academy of Higher Education, India (2005) and a Master’s in Healthcare Administration from Flinders University of South Australia (2018).
Dr. Siva Kumaran does not hold any directorship in other public companies and listed issuers in Malaysia. He has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, he has no conflict of interest with the Company.